Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H28N4O4 |
Molecular Weight | 328.4072 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
InChI
InChIKey=XRQDFNLINLXZLB-CKIKVBCHSA-N
InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
Molecular Formula | C15H28N4O4 |
Molecular Weight | 328.4072 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:43:19 UTC 2023
by
admin
on
Fri Dec 15 15:43:19 UTC 2023
|
Record UNII |
9ZS94HQO3B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB32136
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
154234
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
330600-85-6
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
85202
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
m8534
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | Merck Index | ||
|
8184
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
PERAMIVIR
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
9ZS94HQO3B
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
9ZS94HQO3B
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
C175841
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | |||
|
1598096
Created by
admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
||
|
BINDER->LIGAND |
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
BINDING
|
||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||